Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
2
50%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Recruiting2
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

terminated125%
recruiting250%
completed125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

NCT05483868
recruitingphase_2

Suprachoroidal Administration in Subjects With Metastases to the Choroid

NCT06643884
completedphase_2

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

NCT04417530
terminated

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

NCT05266430

Clinical Trials (4)

Showing 4 of 4 trials
NCT05483868Phase 1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Recruiting
NCT06643884Phase 2

Suprachoroidal Administration in Subjects With Metastases to the Choroid

Recruiting
NCT04417530Phase 2

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Completed
NCT05266430

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4